Constitutive activation of distinct NF-κB signals in EBV-associated nasopharyngeal carcinoma

J Pathol. 2013 Nov;231(3):311-22. doi: 10.1002/path.4239. Epub 2013 Sep 3.

Abstract

As a distinct type of head and neck cancer, non-keratinizing nasopharyngeal carcinoma (NPC) is closely associated with EBV infection and massive lymphoid infiltration. The unique histological features suggest that local inflammation plays an important role in NPC tumourigenesis. We comprehensively characterized NF-κB signalling, a key inflammatory pathway which might contribute to the tumourigenesis of this EBV-associated cancer. By EMSA, western blotting, and immunohistochemical staining, constitutive activation of distinct NF-κB complexes, either p50/p50/Bcl3 or p50/RelB, was found in almost all EBV-positive NPC tumours. siRNA or chemical inhibition of NF-κB signalling significantly inhibited the growth of EBV-positive NPC cells C666-1. Gene expression profiling identified a number of NF-κB target genes involved in cell proliferation, apoptosis, immune response, and transcription. We further confirmed that p50 signals modulate the expression of multiple oncogenes (MYB, BCL2), chemokines, and chemokine receptors (CXCL9, CXCL10, CX3CL1, and CCL20). The findings support a crucial role of these constitutively activated NF-κB signals in NPC tumourigenesis and local inflammation. In addition to expression of the viral oncoprotein LMP1, genetic alteration of several NF-κB regulators (eg TRAF3, TRAF2, NFKBIA, A20) also contributes to the aberrant NF-κB activation in EBV-associated NPC. Except for LMP1-expressing C15 cells, all NPC tumour lines harbour at least one of these genetic alterations. Importantly, missense mutations of TRAF3, TRAF2, and A20 were also detected in 3/33 (9.1%) primary tumours. Taken together with the reported LTBR amplification in 7.3% of primary NPCs, genetic alterations in NF-κB pathways occurred in at least 16% of cases of this cancer. The findings indicate that distinct NF-κB signals are constitutively activated in EBV-positive NPC cells by either multiple genetic changes or EBV latent genes.

Keywords: A20; Epstein-Barr virus; NF-κB; TRAF2; TRAF3; nasopharyngeal carcinoma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Apoptosis
  • B-Cell Lymphoma 3 Protein
  • Base Sequence
  • Carcinoma
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Transformation, Viral*
  • Epstein-Barr Virus Infections / immunology
  • Epstein-Barr Virus Infections / metabolism*
  • Epstein-Barr Virus Infections / virology
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Inflammation Mediators / metabolism
  • Molecular Sequence Data
  • Mutation
  • NF-kappa B / antagonists & inhibitors
  • NF-kappa B / genetics
  • NF-kappa B / metabolism*
  • NF-kappa B p50 Subunit / metabolism
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Neoplasms / genetics
  • Nasopharyngeal Neoplasms / immunology
  • Nasopharyngeal Neoplasms / metabolism*
  • Nasopharyngeal Neoplasms / pathology
  • Nasopharyngeal Neoplasms / virology
  • Proto-Oncogene Proteins / metabolism
  • RNA Interference
  • Signal Transduction* / drug effects
  • Time Factors
  • Transcription Factor RelB / metabolism
  • Transcription Factors / metabolism
  • Transfection

Substances

  • Antineoplastic Agents
  • B-Cell Lymphoma 3 Protein
  • BCL3 protein, human
  • Inflammation Mediators
  • NF-kappa B
  • NF-kappa B p50 Subunit
  • NFKB1 protein, human
  • Proto-Oncogene Proteins
  • RELB protein, human
  • Transcription Factors
  • Transcription Factor RelB